A Phase 3, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits BLyS, in Patients With Systemic Lupus Erythematosus

OBJECTIVE: To assess the efficacy/safety of the B-lymphocyte stimulator inhibitor belimumab/standard-of-care (SOC) versus placebo/SOC in active systemic lupus erythematosus (SLE). METHODS: In a multicenter, randomized, controlled, phase 3 trial, 819 antinuclear antibody- or anti-dsDNA-positive SLE p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheum
Main Authors: Furie, Richard, Petri, Michelle, Zamani, Omid, Cervera, Ricard, Wallace, Daniel J., Tegzová, Dana, Sanchez-Guerrero, Jorge, Schwarting, Andreas, Merrill, Joan T., Chatham, W. Winn, Stohl, William, Ginzler, Ellen M., Hough, Douglas R., Zhong, Z. John, Freimuth, William, van Vollenhoven, Ronald F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007058/
https://ncbi.nlm.nih.gov/pubmed/22127708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.30613
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados